Haynes, D. R.

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint

Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., Atkins, G. J., & Findlay, D. M. (2001) · Rheumatology

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 216

Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases

Rheumatoid Arthritis Research and TherapiesNatural Compounds in Disease Treatment

Cited by 186

Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.

Haynes, D. R. (2003) · Rheumatology

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 157

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone

Bone Metabolism and DiseasesBone Tumor Diagnosis and Treatments

Cited by 105

Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation

Zawawi, M. S. F., Dharmapatni, A. A. S. S. K., Cantley, M. D., McHugh, K. P., Haynes, D. R., & Crotti, T. N. (2012) · Biochemical and Biophysical Research Communications

Bone Metabolism and DiseasesSignaling Pathways in Disease

Cited by 29